Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Erdafitinib; Procedure: Magnetic Resonance Imaging Sponsors: National Cancer Institute (NCI) Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials